Related Experiment Video
Updated: Jun 30, 2026

Rapid and Specific Detection of Acinetobacter baumannii Infections Using a Recombinase Polymerase Amplification/Cas12a-based System
Published on: April 25, 2025
Phenotypic Detection Methods, Clinical Outcomes, and Therapeutic Strategies for OXA-Type Carbapenemase-Producing
Pranay R Ullengala1, Ravindra V Shinde1, Satish R Patil1
1Department of Microbiology, Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth (Deemed to be University), Karad, IND.
Abstract:
Acinetobacter species have emerged as significant nosocomial pathogens, severely complicating treatment protocols in tertiary care settings due to their rapid development of multidrug resistance (MDR). As an opportunistic pathogen, Acinetobacter baumannii is frequently associated with ventilator-associated pneumonia (VAP) and bloodstream infections, carrying substantial mortality rates. The primary mechanism driving this extensive beta-lactam resistance and the focal point of this review is the production of OXA-type carbapenem-hydrolyzing class D β-lactamases (CHDLs), alongside extended-spectrum beta-lactamases (ESBLs). The pathophysiology, virulence factors, clinical symptoms, and epidemiology of these resistant bacteria are all reviewed in this thorough analysis. Further, it describes the essential laboratory challenges and standard phenotypic methodologies needed to precisely isolate and profile these highly resistant Acinetobacter species from clinical specimens, as well as the molecular mechanisms underlying carbapenem resistance. Finally, given the high prevalence of these isolates in Indian intensive care units, this review evaluates the severe clinical outcomes associated with these strains and highlights essential therapeutic strategies. It emphasizes the urgent need for tailored combination therapies and explores the efficacy of novel targeted treatments, such as the sulbactam-durlobactam combination, in managing severe OXA-driven infections.
Insights
Multidrug-resistant Acinetobacter baumannii, a major cause of hospital infections, is often resistant to carbapenems due to OXA-type beta-lactamases. New therapies are crucial for managing these severe infections.
Area of Science:
- Clinical Microbiology
- Infectious Diseases
- Antimicrobial Resistance
Background:
- Acinetobacter species are significant nosocomial pathogens, particularly Acinetobacter baumannii.
- These bacteria cause severe infections like ventilator-associated pneumonia and bloodstream infections with high mortality rates.
- Rapid development of multidrug resistance (MDR) complicates treatment in tertiary care settings.
Purpose of the Study:
- To review the pathophysiology, virulence, clinical symptoms, and epidemiology of MDR Acinetobacter species.
- To discuss laboratory challenges and methodologies for isolating and profiling resistant strains.
- To evaluate clinical outcomes and therapeutic strategies for OXA-driven carbapenem resistance in India.
Main Methods:
- Literature review focusing on OXA-type carbapenem-hydrolyzing class D beta-lactamases (CHDLs) and extended-spectrum beta-lactamases (ESBLs).
- Analysis of laboratory diagnostic methods for isolation and characterization of resistant Acinetobacter.
- Evaluation of clinical data and treatment outcomes from Indian intensive care units.
Main Results:
- OXA-type CHDLs are a primary mechanism for beta-lactam resistance in Acinetobacter.
- Specific laboratory techniques are essential for accurate identification of these resistant pathogens.
- High prevalence of these resistant strains in Indian ICUs is associated with severe clinical outcomes.
Conclusions:
- Effective management of MDR Acinetobacter requires understanding resistance mechanisms and clinical impact.
- Tailored combination therapies and novel treatments like sulbactam-durlobactam show promise.
- Urgent need for improved therapeutic strategies to combat severe OXA-driven infections.
Related Concept Videos
Clinical Significance of Antibiotic Resistance
Acute Pyelonephritis II: Diagnostic Studies and Management
Antimicrobial Effectiveness
Automated Microbial Diagnostics
Antibiotic Selection
Rapid Identification of Pathogens
